Comparative analysis of the immunoprotective abilities of glycosylated and deglycosylated parainfluenza virus type 3 surface glycoproteins

Ewasyshyn, M.; Bonneau, A.-M.; Usman, Saheed Opeyemi; Scollard, N.; Klein, Michel

doi:10.1099/0022-1317-74-12-2781

Cited by 4 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deglycosylation ofthe lectin-purified HN and F proteins with endoglycosidase F did not affect the ability of the alum-adjuvanted proteins to protect hamsters against live virus challenge. These results suggested that the carbohydrate moieties of the HN and F proteins were not necessary for eliciting a protective response in hamsters (Ewasyshyn et al, 1993).…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Vaccine Design

1997

View full text Add to dashboard Cite

Aseries presenting the results of aetlvities sponsored by the NA TO Seienee Committee, whieh aims at the dissemination of advaneed seientlflc and technologleal knowledge, with a vlew to strengthenlng links between seientific communities. The series is publlshed by an International board of publlshers in conjunctlon with the NATO Sclentific Affairs Division A Llfe Sclences B Physlcs All rights reservedNo part 01 thls book may be reproduced, stored in a retrleval syst~m, or transmitted in any lorm or by any means, electronlc, mechanlcal, photocopylng, mlcrolilming. recording, or otherwlse, wlthout written perm Iss Ion lrom the Publlsher ISBN 978-1-4899-0064-7 ISBN 978-1-4899-0062-3 (eBook) PREFACEDuring the last decade or so vaccine development has been facilitated by rapid advances in the molecular and cell biology ofthe immune system. This has laid the foundations of a new generation of vaccines exemplified by subunit vaccines produced through gene cloning and by synthetic peptides mimicking small regions ofproteins on the outer coat ofviruses. However, as subunit and peptide vaccines are only weakly or non-immunogenic, there is areal need for strategies to improve their potency.This book contains the proceedings of the 5th NATO Advanced Studies Institute (ASI), "Vaccine Design: The Role of Cytokine Networks," held at Cape Sounion Beach, Greece, during 24 June-5 July 1996 and deals in depth with the role ofbasic immunology in the regulation of immunity and vaccine design. Special emphasis is given to the use of cytokines in conjuction with vaccines with the aim ofimproving their potency or the use ofvaccines designed to improve cytokine production.

show abstract

Section: Discussionmentioning

confidence: 90%

“…A PIV -3 challenge virus is currently available. (Ewasyshyn et al, 1993). The encouraging immunogenicity results provide the basis for the continued development ofthis prototype PIV -1,2,3 vaccine.…”

Section: Discussionmentioning

confidence: 90%

Vaccine Design

1997

View full text Add to dashboard Cite

show abstract

“…Although the role of hPIV HN N-glycosylation has not been explored extensively, N-linked glycans have been shown to be important in host-receptor interactions (Chu et al 2013;Gorman, Pridgen, and Portner 1991) and immune recognition (Ewasyshyn et al 1993). Site-directed mutagenesis of all three hPIV3 HN N-glycosylation residues, followed by transient cell surface expression of these HN mutants resulted in decreased haemagglutinin activity of HN (Chu et al 2013).…”

Section: Glycosylationmentioning

confidence: 99%

“…This suggests that N-linked glycans are primarily essential in the haemagglutinin, but not in the neuraminidase activity of HN. In hPIV3, a complete loss of N-linked glycans on copurified hPIV3 HN and F proteins decreased the magnitude of the primary immune response in hamsters, with a very limited effect on the secondary antibody response (Ewasyshyn et al 1993). However, the relevance of these findings to human infection needs to be investigated using whole hPIV (Mishin et al 2010;Porotto et al 2007;Streltsov et al 2015).…”

Section: Glycosylationmentioning

confidence: 99%

New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase

et al. 2019

View full text Add to dashboard Cite

• Human parainfluenza viruses (hPIVs) cause significant disease in infants, the elderly and immunocompromised persons. • Haemagglutinin-neuraminidase (HN) has multiple roles in the hPIV lifecycle, making it an attractive antiviral drug target. • Computational modelling and structure-based inhibitor studies have enhanced the development of potent hPIV3 HN inhibitors. • Current inhibitor strategies targeting HN are primarily based on sialic acid analogues. • Identification of new targets and inhibitor scaffolds could prove worthwhile in the fight against hPIVs.

show abstract

“…I Jlg by the addition of aluminum phosphate, Syntex's SAF-MF formulation or Freund's adjuvant. Deglycosylation of the lectin-purified HN and F proteins with endoglycosidasc F did not affect the ability of the proteins to protect hamsters against live virus challenge thereby suggesting that the carbohydrate moieties of the HN and F proteins were not necessary for eliciting a protective response in hamsters 7 .…”

mentioning

confidence: 99%